OA10616A - Synergistic combinations of zidovudine 1592u89 and3tc or ftc - Google Patents

Synergistic combinations of zidovudine 1592u89 and3tc or ftc Download PDF

Info

Publication number
OA10616A
OA10616A OA70075A OA70075A OA10616A OA 10616 A OA10616 A OA 10616A OA 70075 A OA70075 A OA 70075A OA 70075 A OA70075 A OA 70075A OA 10616 A OA10616 A OA 10616A
Authority
OA
OAPI
Prior art keywords
amino
cis
zidovudine
purin
oxathiolan
Prior art date
Application number
OA70075A
Other languages
English (en)
Inventor
David Walter Barry
Martha Heider St Clair
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of OA10616A publication Critical patent/OA10616A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
OA70075A 1995-03-30 1997-09-17 Synergistic combinations of zidovudine 1592u89 and3tc or ftc OA10616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations

Publications (1)

Publication Number Publication Date
OA10616A true OA10616A (en) 2001-03-15

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70075A OA10616A (en) 1995-03-30 1997-09-17 Synergistic combinations of zidovudine 1592u89 and3tc or ftc

Country Status (36)

Country Link
US (1) US6417191B1 (pt)
EP (1) EP0817637B1 (pt)
JP (1) JP2954357B2 (pt)
KR (1) KR100542536B1 (pt)
CN (1) CN1103593C (pt)
AP (1) AP652A (pt)
AT (1) ATE220551T1 (pt)
AU (1) AU715213B2 (pt)
BR (3) BR9607851B1 (pt)
CA (1) CA2216634C (pt)
CZ (1) CZ295940B6 (pt)
DE (3) DE122005000029I1 (pt)
DK (1) DK0817637T3 (pt)
EA (1) EA000626B3 (pt)
EE (1) EE04047B1 (pt)
ES (1) ES2179193T3 (pt)
FR (1) FR05C0022I2 (pt)
GE (1) GEP20022647B (pt)
HK (1) HK1009401A1 (pt)
HU (1) HU224010B1 (pt)
IL (1) IL117727A (pt)
LU (1) LU91171I2 (pt)
MX (1) MX9707316A (pt)
MY (1) MY115461A (pt)
NL (1) NL300195I2 (pt)
NO (2) NO313787B1 (pt)
NZ (1) NZ306419A (pt)
OA (1) OA10616A (pt)
PL (1) PL187085B1 (pt)
PT (1) PT817637E (pt)
RO (1) RO117995B1 (pt)
SI (1) SI0817637T1 (pt)
SK (1) SK283825B6 (pt)
TR (1) TR199701074T1 (pt)
UA (1) UA60293C2 (pt)
WO (1) WO1996030025A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9903249A3 (en) * 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
EP0979082A1 (en) * 1997-05-17 2000-02-16 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
WO1999060988A2 (en) * 1998-05-29 1999-12-02 University Of Florida Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
AU2010251880B2 (en) 2009-05-27 2015-07-30 Biotempus Pty Ltd Methods of treating diseases
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
AU1787492A (en) * 1991-05-16 1992-12-30 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
CZ429398A3 (cs) 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CZ309097A3 (cs) 1998-05-13
BRPI9612992B1 (pt) 2020-08-04
IL117727A0 (en) 1996-07-23
EP0817637B1 (en) 2002-07-17
BR9607851A (pt) 1998-07-21
PL187085B1 (pl) 2004-05-31
DE69622386T2 (de) 2003-02-13
NL300195I1 (nl) 2005-08-01
DE122005000029I2 (de) 2006-04-27
ATE220551T1 (de) 2002-08-15
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
NL300195I2 (nl) 2005-11-01
US6417191B1 (en) 2002-07-09
EP0817637A1 (en) 1998-01-14
TR199701074T1 (xx) 1998-02-21
CN1185110A (zh) 1998-06-17
BR9607851B1 (pt) 2009-01-13
KR19980703420A (ko) 1998-11-05
AU5497296A (en) 1996-10-16
UA60293C2 (uk) 2003-10-15
RO117995B1 (ro) 2002-12-30
CN1103593C (zh) 2003-03-26
WO1996030025A1 (en) 1996-10-03
JP2954357B2 (ja) 1999-09-27
NO974510L (no) 1997-09-29
LU91171I2 (fr) 2005-07-04
SK129597A3 (en) 1998-07-08
HU224010B1 (hu) 2005-04-28
CA2216634A1 (en) 1996-10-03
NO974510D0 (no) 1997-09-29
ES2179193T3 (es) 2003-01-16
FR05C0022I1 (pt) 2005-06-10
EA199700203A1 (ru) 1998-02-26
PL322532A1 (en) 1998-02-02
CA2216634C (en) 2004-07-20
EA000626B1 (ru) 1999-12-29
BRPI9607851B8 (pt) 2019-11-05
NO313787B1 (no) 2002-12-02
AP652A (en) 1998-06-19
SK283825B6 (sk) 2004-02-03
EA000626B3 (ru) 2016-04-29
EE04047B1 (et) 2003-06-16
MY115461A (en) 2003-06-30
CZ295940B6 (cs) 2005-12-14
EE9700240A (et) 1998-04-15
HUP9801571A3 (en) 2001-04-28
KR100542536B1 (ko) 2006-03-23
DK0817637T3 (da) 2002-11-11
LU91171I9 (pt) 2018-12-28
IL117727A (en) 1999-11-30
NO2005014I1 (no) 2005-06-06
DE122005000029I1 (de) 2005-10-06
MX9707316A (es) 1997-11-29
SI0817637T1 (en) 2002-10-31
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
JPH10511682A (ja) 1998-11-10
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
AU715213B2 (en) 2000-01-20
HK1009401A1 (en) 1999-09-10
FR05C0022I2 (pt) 2005-10-21
NO2005014I2 (no) 2008-02-11

Similar Documents

Publication Publication Date Title
OA10616A (en) Synergistic combinations of zidovudine 1592u89 and3tc or ftc
AU727983B2 (en) Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
US6486136B1 (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
EP0979082A1 (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
US20020002180A1 (en) Antiviral combinations
EP1113803A1 (en) Antiviral combinations comprising lamivudine and abacavir
WO1998052571A1 (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of